Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7465795 | 0.89 | L3MBTL1 (0.56) | L3MBTL1USP2GAATSHRMEN1 | |
| SCHEMBL23571859 | 0.84 | USP2 (0.65) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL29823082 | 0.84 | USP2 (0.65) | USP2GAATSHRMEN1KMT2A | |
| SCHEMBL7476434 | 0.83 | L3MBTL1 (0.63) | L3MBTL1USP2GAATSHRMEN1 | |
| SCHEMBL20414554 | 0.83 | L3MBTL1 (0.63) | L3MBTL1USP2GAATSHRMEN1 | |
| SCHEMBL2101384 | 0.83 | L3MBTL1 (0.63) | L3MBTL1USP2GAATSHRMEN1 | |
| SCHEMBL18209180 | 0.83 | L3MBTL1 (0.63) | L3MBTL1USP2GAATSHRMEN1 | |
| SCHEMBL7468675 | 0.83 | L3MBTL1 (0.63) | L3MBTL1USP2GAATSHRMEN1 | |
| SCHEMBL17055837 | 0.83 | L3MBTL1 (0.63) | L3MBTL1USP2GAATSHRMEN1 | |
| SCHEMBL3597209 | 0.83 | L3MBTL1 (0.63) | L3MBTL1USP2GAATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010123139-A1 | ARYLCARBOXAMIDE DERIVATIVE HAVING SULFAMOYL GROUP | 持田製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-0869949-B1 | BENZOXAZINE ANTIMICROBIAL AGENTS | ORTHO MCNEIL PHARM INC (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1218370-A2 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Aventis Pharma S.A. (FR) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001025227-A2 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA S.A. (FR) | 2001-04-12 | — | — | WO | disclosed |
| US-5854242-A | Benzoxazine antimicrobial agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| EP-0869949-A1 | BENZOXAZINE ANTIMICROBIAL AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5696117-A | BACTERICIDE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1997017333-A1 | BENZOXAZINE ANTIMICROBIAL AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | L3MBTL1 1736/4885USP2 2244/4885GAA 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.